Jazz Pharmaceuticals (JAZZ) Short-term Investments (2011 - 2017)
Jazz Pharmaceuticals (JAZZ) recorded quarterly Short-term Investments of $200.0 million in Q3 2017, up 150.0% quarter-over-quarter from $80.0 million in Q2 2017, and up 236.6% on a YoY basis from $59.4 million in Q3 2016.
Jazz Pharmaceuticals (JAZZ) Short-term Investments (2011 - 2017) Analysis & Trends
Jazz Pharmaceuticals' Short-term Investments history runs 4 years deep, the most recent figure standing at $200.0 million for Q3 2017.
- In Q3 2017, Short-term Investments rose 236.6% year-over-year to $200.0 million; the TTM figure through Sep 2017 stood at $200.0 million (up 236.6% YoY), while the FY2016 annual figure was $60.0 million, changed N/A from the prior year.
- Short-term Investments was $200.0 million for Q3 2017 at Jazz Pharmaceuticals, up from $80.0 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $200.0 million in Q3 2017 to a low of $764000.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Jazz Pharmaceuticals | 13.91 Bn | 12.06 Bn | 934.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 200.00 Mn |
| Jun 30, 2017 | 80.00 Mn |
| Mar 31, 2017 | 60.00 Mn |
| Dec 31, 2016 | 60.00 Mn |
| Sep 30, 2016 | 59.42 Mn |
| Jun 30, 2016 | 48.41 Mn |
| Mar 31, 2016 | 764,000.00 |
| Mar 31, 2012 | 73.56 Mn |
| Dec 31, 2011 | 75.82 Mn |
| Sep 30, 2011 | 12.13 Mn |